Search

Your search keyword '"Kitko, Carrie L."' showing total 175 results

Search Constraints

Start Over You searched for: Author "Kitko, Carrie L." Remove constraint Author: "Kitko, Carrie L." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
175 results on '"Kitko, Carrie L."'

Search Results

3. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

4. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

5. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

6. Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

7. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

8. A Day 14 Endpoint for Acute GVHD Clinical Trials

9. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

10. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

11. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study

12. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

13. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

16. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis

17. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

18. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

19. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

20. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

21. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis

22. Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

23. Ibrutinib for Therapy of Steroid-Refractory Chronic Graft Vs. Host Disease: A Multicenter Real-World Analysis

24. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)

26. Graft Vs Host Disease (GVHD) in Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients and Impact on Overall Survival: A CIBMTR Analysis

27. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd

28. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors

30. The utility of biomarkers in acute GVHD prognostication

32. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry

33. Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients

35. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.

36. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease

37. Patient-reported treatment response in chronic graft-versus-host disease

38. Incidence of bacterial blood stream infections in patients with acute GVHD

39. Applying a risk prediction model for bloodstream infection in a febrile, nonseverely neutropenic cohort of pediatric stem cell transplant patients

40. CAR-T Prescriber Preferences in Adolescents and Young Adults with B-ALL

42. De Novo Late Acute Gvhd: Incidence, Outcomes, and Impact of Biomarkers Compared to Classic Acute Gvhd

43. ABO Incompatibility Did Not Impact Outcomes after Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide for Patients with Sickle Cell Disease: Single Center Experience

44. The Combination of Rituximab, Plasmapheresis, Intravenous Immunoglobulins and Pre-Transplant Immunosuppression Is an Effective Desensitization Strategy for Patients with Sickle Cell Disease and High Donor Specific Anti-Human Leukocyte Antigen Titer Undergoing Haploidentical Bone Marrow Transplant

45. Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants

46. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

47. Three-year results from phase 1 of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

48. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE / PBMTC 1202 study

49. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.

Catalog

Books, media, physical & digital resources